Faculty

Pharmaceutics

• K. Nagarajan, Snigdha Bhardwaj (2025). Docking and AI Based Classification cum Recurrent Neural Network Validation for predicting Antitubercular Leads against DPRE1 Enzyme target. Current Proteomics. ISSN:1875-6247
• Kandasamy Nagarjan, Lalit Mohan Nainwal, Snigdha Bhardwaj (2025). Analytical techniques for the quantification and validation of Resveratrol: A review. Anti-inflammatory and Anti-allergy agents in Medicinal Chemistry. ISSN:1871-5230
• Kandasamy Nagarjan, Snigdha Bhardwaj, Surbhi Kamboj (2025). Method Development and Validation of Orlistat by Using RP-HPLC. Current Pharmaceutical Analysis. ISSN:1875-676X
• Kandasamy Nagarajan, Snigdha Bhardwaj (2025). Analytical method development and validation of Efavirenz by using RP-HPLC. International Journal of Pharmaceutical Investigation. ISSN:2230-973X

• Binkey Srivastava, Kandasamy Nagarajan, Garima Kapoor, Richa Goel, Snigdha Bhardwaj, Parul Grover (2024-08-02). Synthesis of Smaller chain peptide candidates against M. Tuberculosis and mitigating lung injury associated with methotrexate treatment. Indian Patent Office . Application Number:202411054973 A
• K. Nagarajan, Richa Goel, Vidhu Saxena, Snigdha Bhardwaj, Garima Kapoor (2025-04-04). Peptide Therapeutics for Managing Neonatal Acute Lung Injury. Indian Patent Office . Application Number:202511027461 A
• K. Nagarjan, Richa Goel, Snigdha Bhardwaj, Sheena Mehta, Vidhu Saxena (2025-06-13). TLR-9 receptor in Tryptophan and Arginine peptide-mediated immunomodulation for tuberculosis therapy. Indian Patent Office . Application Number:202511050369 A

• Dr. K. Nagarajan, Garima Kapoor, Richa Goel, Snigdha Bhardwaj (2024-25). Synthesis of Smaller chain peptide candidates against M. Tuberculosis and mitigating lung injury associated with methotrexate treatment. AICTE-KAPILA . Amount:5600